What is it about?
Alzheimer's disease is a debilitating neurodegenerative disorder that relentlessly progresses over time. As the eye is an expansion of the central nervous system (CNS), checking on changes within the eye’s tissues may lead to creating an arrangement of non-invasive, differential symptomatic tests for AD that can be advance connected to other diseases. Recently, there are challenges in diagnosing AD especially ophthalmic biomarkers and eye can be a mirror to numerous neural and systemic disarranges. The only optically visible nerve tissue is the retina, so, the aim of the present work to evaluate the characteristic molecular structure changes in retina due to AD induced by AlCl3 in rats using Fourier-transform infrared spectroscopy
Featured Image
Photo by Colin Lloyd on Unsplash
Why is it important?
Ocular biomarkers might improve the accuracy of Alzheimer disease diagnosis and might also serve as indirect measures of disease severity. The development of new therapies for Alzheimer disease has become of increasing societal importance given our aging population and increasing longevity, combined with the fact that this disease typically begins late in life.
Perspectives
This article was an interesting as it has collaborating co-authors and lead to discover a new approach for Alzheimer disease early diagnosis.
Eman Aly
Research Institute of Ophthalmology
Read the Original
This page is a summary of: Linking Cognitive Impairment with Amyloid-β Accumulation in Alzheimer’s Disease: Insights from Behavioral Tests and FTIR Spectroscopy, Journal of Alzheimer s Disease Reports, November 2023, IOS Press,
DOI: 10.3233/adr-230051.
You can read the full text:
Contributors
The following have contributed to this page
